66 related articles for article (PubMed ID: 184804)
1. Cardiovascular effects of UK 14,275: evaluation of a new phosphodiesterase inhibitor with inotropic properties in animals and human volunteers [proceedings].
Follath F; Kersting F; Lewis GR; Dollery CT
Br J Clin Pharmacol; 1975 Aug; 2(4):372P-373P. PubMed ID: 184804
[No Abstract] [Full Text] [Related]
2. A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties.
Alvarez R; Banerjee GL; Bruno JJ; Jones GL; Littschwager K; Strosberg AM; Venuti MC
Mol Pharmacol; 1986 Jun; 29(6):554-60. PubMed ID: 3012320
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo myocardial effects of a cyclic AMP phosphodiesterase inhibitor structurally related to natural cardenolides.
Prigent AF; Nemoz G; Roche M; Pacheco H
Arch Int Pharmacodyn Ther; 1979 Sep; 241(1):131-52. PubMed ID: 230791
[TBL] [Abstract][Full Text] [Related]
4. Proceedings: Enhancement of ADP-induced platelet aggregation by isometric hand-grip excercise in sclerotic patients and its prevention by EG-626, cAMPPDE inhibitor.
Sano T; Motimiya T; Yamazaki H; Shinamoto T
Thromb Diath Haemorrh; 1975 Sep; 34(1):344. PubMed ID: 171796
[No Abstract] [Full Text] [Related]
5. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase inhibitors as antiplatelet agents in vascular surgery.
Kambayashi J; Watase M; Kawasaki T; Shiba E; Sakon M; Mori T; Isaka Y; Kimura K; Kamada T
Adv Second Messenger Phosphoprotein Res; 1992; 25():383-93. PubMed ID: 1313269
[No Abstract] [Full Text] [Related]
7. Demonstration of functional compartments of cyclic AMP in rat platelets by the use of phosphodiesterase inhibitors.
Ashida S; Sakuma K
Adv Second Messenger Phosphoprotein Res; 1992; 25():229-39. PubMed ID: 1313259
[No Abstract] [Full Text] [Related]
8. Multiple molecular forms of phosphodiesterase and the regulation of cardiac muscle contractility.
Weishaar RE; Kobylarz-Singer DC; Quade MM; Steffen RP; Kaplan HR
J Cyclic Nucleotide Protein Phosphor Res; 1986-1987; 11(7):513-27. PubMed ID: 2831259
[TBL] [Abstract][Full Text] [Related]
9. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1.
Lorthiois E; Bernardelli P; Vergne F; Oliveira C; Mafroud AK; Proust E; Heuze L; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Wrigglesworth R; Descours A; Soulard P; Berna P
Bioorg Med Chem Lett; 2004 Sep; 14(18):4623-6. PubMed ID: 15324876
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cyclic AMP phosphodiesterase activity and myocardial contractility: effects of cilostamide, a novel PDE inhibitor, and methylsiobutylxanthine on rabbit and canine ventricular muscle.
Endoh M; Satoh K; Yamashita S
Eur J Pharmacol; 1980 Aug; 66(1):43-52. PubMed ID: 6157546
[No Abstract] [Full Text] [Related]
11. Cyclic-AMP-dependent positive chrono- and inotropic responses in the blood-perfused dog atrium.
Chiba S; Karasawa Y; Furukawa Y
Adv Second Messenger Phosphoprotein Res; 1992; 25():363-72. PubMed ID: 1372814
[No Abstract] [Full Text] [Related]
12. Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds.
de Cheffoy de Courcelles D; de Loore K; Freyne E; Janssen PA
J Pharmacol Exp Ther; 1992 Oct; 263(1):6-14. PubMed ID: 1328613
[TBL] [Abstract][Full Text] [Related]
13. QSAR study of phosphodiesterase inhibitory activity of imidazo[2,1-b]-quinazolines: active site analysis.
Prabhakar YS
Drug Des Deliv; 1989 Dec; 5(2):81-91. PubMed ID: 2577989
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular responses to a newly developed phosphodiesterase inhibitor, DN-9693 [7-pyperidinyl-1,2,3,5-tetrahydroimidazo (2,1-b)-quinazolin-2-one.HCl] in dog cross-circulated atrial and ventricular preparations.
Akahane K; Furukawa Y; Haniuda M; Karasawa Y; Chiba S
Jpn Heart J; 1989 Nov; 30(6):903-15. PubMed ID: 2561162
[TBL] [Abstract][Full Text] [Related]
15. DN 9693: a phosphodiesterase inhibitor with a platelet membrane effect.
Jackson C; Ball J; Peel J; Lawry J; Greaves M; Preston FE
Thromb Haemost; 1989 Apr; 61(2):266-9. PubMed ID: 2546286
[TBL] [Abstract][Full Text] [Related]
16. Interaction of four methylxanthine compounds and norepinephrine on cardiac phosphorylase activation and cardiac contractility.
McNeill JH; Brenner MJ; Muschek LD
Recent Adv Stud Cardiac Struct Metab; 1973; 3():261-73. PubMed ID: 4377599
[No Abstract] [Full Text] [Related]
17. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
Muggli R; Tschopp TB; Mittelholzer E; Baumgartner HR
J Pharmacol Exp Ther; 1985 Oct; 235(1):212-9. PubMed ID: 2995647
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries.
Birk S; Edvinsson L; Olesen J; Kruuse C
Eur J Pharmacol; 2004 Apr; 489(1-2):93-100. PubMed ID: 15063160
[TBL] [Abstract][Full Text] [Related]
19. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: Optimization of 5,8-disubstituted derivatives.
Bernardelli P; Lorthiois E; Vergne F; Oliveira C; Mafroud AK; Proust E; Pham N; Ducrot P; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Chevalier E; Descours A; Berlioz-Seux F; Berna P; Li M
Bioorg Med Chem Lett; 2004 Sep; 14(18):4627-31. PubMed ID: 15324877
[TBL] [Abstract][Full Text] [Related]
20. The inotropic effects of UK 14,275, a phosphodiesterase inhibitor, in man.
Jackson PG; Jackson G; Kitson D; Jewitt DE
Br J Clin Pharmacol; 1978 Jan; 5(1):7-11. PubMed ID: 619936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
